Perspective: microbial interventions in the urinary tract

Abstract

Despite multiple advances in medicine, the management of urinary tract infections (UTIs) in women has remained stalled for decades. To prevent the development of symptomatic recurrences, low-dose antibiotics are the mainstay, while alternative approaches have been attempted with limited success. The use of probiotics was first considered forty years ago, and while some promising studies have been published, additional evidence in larger patient groups is needed to recommend specific strains as a primary preventive regimen. Overall, the role of beneficial microbes in reducing the risk of UTI and other urological diseases, such as urolithiasis, remains a target for researchers. The aim of this perspective is to offer a viewpoint on the status of this approach and recommendations for how to develop novel probiotic therapies.

Keywords

Urinary tract / probiotics / beneficial microbes / infection / calculi

References

[1] Bruce AW,Hassan A.Recurrent urethritis in women.Can Med Assoc J1973;108:973-6 PMCID:PMC1941341

[2] Reid G,Bruce AW.Examination of strains of lactobacilli for properties that may influence bacterial interference in the urinary tract.J Urol1987;138:330-5

[3] Velraeds MM,Reid G.Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates.Appl Environ Microbiol1996;62:1958-63 PMCID:PMC167974

[4] Reid G,Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Available from: https://www.scienceopen.com/document?vid=496f67cb-83ec-4bcb-8f78-073ecc9eac75 [Last accessed on 16 Jan 2023]

[5] Reid G,Heinemann C.Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora.FEMS Immunol Med Microbiol2001;32:37-41

[6] Reid G,Erb J.Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women.FEMS Immunol Med Microbiol2003;35:131-4

[7] Anukam K,Ahonkhai I.Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial.Microbes Infect2006;8:1450-4

[8] Reid G.How Do Lactobacilli search and find the vagina?.Microorganisms2023;11:148 PMCID:PMC9861324

[9] Stapleton AE,Hooton TM.Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.Clin Infect Dis2011;52:1212-7 PMCID:PMC3079401

[10] Miller AW,Fitzpatrick K,Tasian G.Mechanisms of the intestinal and urinary microbiome in kidney stone disease.Nat Rev Urol2022;19:695-707

[11] Schwaderer AL.The association between bacteria and urinary stones.Ann Transl Med2017;5:32 PMCID:PMC5300853

[12] Al KF,Daisley BA.Ureteral stent microbiota is associated with patient comorbidities but not antibiotic exposure.Cell Rep Med2020;1:100094

[13] Liu F,Wu Y.The pelvis urinary microbiome in patients with kidney stones and clinical associations.BMC Microbiol2020;20:336 PMCID:PMC7643416

[14] Flores-Mireles AL,Caparon M.Urinary tract infections: epidemiology, mechanisms of infection and treatment options.Nat Rev Microbiol2015;13:269-84 PMCID:PMC4457377

[15] Subashchandrabose S.Virulence and fitness determinants of uropathogenic Escherichia coli.Microbiol Spectr2015;3 PMCID:PMC4566162

[16] Lewis AL.Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models.GMS Infect Dis2020;8:Doc02 PMCID:PMC7186798

[17] Beerepoot MA,Nys S.Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women.Arch Intern Med2012;172:704-12

[18] Sadeghi-Bojd S,Mazaheri M,Assadi F.Efficacy of probiotic prophylaxis after the first febrile urinary tract infection in children with normal urinary tracts.J Pediatric Infect Dis Soc2020;9:305-10

[19] Wolff BJ,Joyce CJ,Mueller ER.Oral probiotics and the female urinary microbiome: a double-blinded randomized placebo-controlled trial.Int Urol Nephrol2019;51:2149-59

[20] Sarkissian CA,Mobley HLT.UTI patients have pre-existing antigen-specific antibody titers against UTI vaccine antigens.Vaccine2019;37:4937-46 PMCID:PMC6812515

[21] Butler D,Wan MLY,Wullt B.Immunomodulation therapy offers new molecular strategies to treat UTI.Nat Rev Urol2022;19:419-37 PMCID:PMC9214477

[22] Wullt B,Ambite I,Krintel C.Immunomodulation-a molecular solution to treating patients with severe bladder pain syndrome?.Eur Urol Open Sci2021;31:49-58 PMCID:PMC8385293

[23] Biehl LM,Farowski F.Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection.Infection2018;46:871-4

[24] Staley C,Graiziger CT,Khoruts A.Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection.J Antimicrob Chemother2017;72:522-8 PMCID:PMC6075516

[25] Li N,Liu H.Horizontal transfer of vanA between probiotic Enterococcus faecium and Enterococcus faecalis in fermented soybean meal and in digestive tract of growing pigs.J Anim Sci Biotechnol2019;10:36 PMCID:PMC6460829

[26] Sanders ME,Haller D.Safety assessment of probiotics for human use.Gut Microbes2010;1:164-85 PMCID:PMC3023597

[27] Ouwehand AC,Hibberd AA,Stahl B.Probiotic approach to prevent antibiotic resistance.Ann Med2016;48:246-55

[28] Kirjavainen PV,Carter DE,Reid G. Expression of anti-microbial defense factors in vaginal mucosa following exposure to Lactobacillus rhamnosus GR-1. Available from: https://ir.lib.uwo.ca/mnipub/270/ [Last accessed on 16 Jan 2023]

[29] Abbasian B,O'Gorman DB.Potential role of extracellular ATP released by bacteria in bladder infection and contractility.mSphere2019;4:e00439-19 PMCID:PMC6731529

[30] Stuivenberg GA,Akouris PP,Reid G.Probiotic bifidobacteria mitigate the deleterious effects of para-cresol in a Drosophila melanogaster toxicity model.mSphere2022:e0044622 PMCID:PMC9769938

[31] Ali SN,Ali AN.Drosophila melanogaster as a function-based high-throughput screening model for antinephrolithiasis agents in kidney stone patients.Dis Model Mech2018;11:dmm035873 PMCID:PMC6262805

[32] Macklaim JM,Anukam KC,Reid G.At the crossroads of vaginal health and disease, the genome sequence of Lactobacillus iners AB-1.Proc Natl Acad Sci USA2011;108 Suppl 1:4688-95 PMCID:PMC3063587

[33] Reid G,Bruce AW.Implantation of Lactobacillus casei var rhamnosus into the vagina.Lancet1994;344:1229

[34] Baker EP,Kohler KM.Evolution of host-microbe cell adherence by receptor domain shuffling.Elife2022;11:e73330 PMCID:PMC8860441

[35] Puebla-Barragan S,Jafelice S.Topical probiotics for women’s urogenital health: selection of an oil-based carrier.OBM Integrat Comp Med2021;6:10

[36] Puebla-Barragan S.Probiotics in cosmetic and personl care products: trends and challenges.Molecules2021;26:1249

[37] Ya W,Miller LE.Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study.Am J Obstet Gynecol2010;203:120.e1-6

[38] Petricevic L.The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis.BJOG2008;115:1369-74

[39] AEProbio. Clinical Guide to Probiotic Products Available in Canada. Available from: www.probioticchart.ca [Last accessed on 16 Jan 2023]

[40] Dausset C,Miquel S.Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35.Sci Rep2020;10:17074 PMCID:PMC7553951

[41] Pompei A,Amaretti A,Matteuzzi D.Folate production by bifidobacteria as a potential probiotic property.Appl Environ Microbiol2007;73:179-85 PMCID:PMC1797147

[42] Raz R.A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.N Engl J Med1993;329:753-6

[43] Wigner P,Saluk-Bijak J.Probiotics in the prevention of the calcium oxalate urolithiasis.Cells2022;11:284 PMCID:PMC8773937

[44] Azcarate-Peril MA,Hassan HM.Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from Lactobacillus acidophilus.Appl Environ Microbiol2006;72:1891-9 PMCID:PMC1393175

[45] Watterson JD,Beiko DT.Oxalate-degrading enzymes from Oxalobacter formigenes: a novel device coating to reduce urinary tract biomaterial-related encrustation.J Endourol2003;17:269-74

[46] Bassetti M,Matsunaga Y.Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.Lancet Infect Dis2021;21:226-240